Sansoz has filed the case with a hope that the court will find that its generic version of Novo Nordisk’s diabetes drug Prandin (repaglinide) is non-infringing, Bloomberg reported.
Sandoz intends to market a generic version of Prandin in low cost.
Prandin (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus).